<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757443</url>
  </required_header>
  <id_info>
    <org_study_id>PCr-in-CS</org_study_id>
    <nct_id>NCT02757443</nct_id>
  </id_info>
  <brief_title>Myocardial Protection With Phosphocreatine in High-RIsk Cardiac SurgEry Patients</brief_title>
  <acronym>PRISE</acronym>
  <official_title>Myocardial Protection With Phosphocreatine in High-RIsk Cardiac SurgEry Patients: a Single-center Randomised Double-blind Placebo-controlled Exploratory Pilot Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is evidence on the role of the phosphotransfer system in the energy metabolism of the&#xD;
      heart, with altered energetics playing an important role in the mechanisms of heart failure.&#xD;
      Phosphocreatine plays an important part in the energy heart system. The investigators have&#xD;
      just performed a systematic review and meta-analysis of randomized controlled trials (RCTs)&#xD;
      and matched studies that compared phosphocreatine with placebo or standard treatment in&#xD;
      patients with coronary artery disease or chronic heart failure or in those undergoing cardiac&#xD;
      surgery. Patients receiving phosphocreatine had lower all-cause mortality as well as improved&#xD;
      cardiac outcomes when compared to the control group, however, the quality of the included&#xD;
      studies was low. Thus, the investigators plan to conduct an exploratory high quality RCT to&#xD;
      investigate whether providing phosphocreatine compared to placebo improves the myocardial&#xD;
      protection in high-risk patients scheduled for cardiac surgery and to determine the best&#xD;
      research endpoint for future trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">May 2021</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak concentration of Troponin I</measure>
    <time_frame>From the randomization to the postoperative day 3 (POD 3)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The need for (yes/no), and dosage (inotropic score) of, inotropic agents</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need for (yes/no), the number of and the dosage of, defibrillation</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of new-onset moderate and severe arrhythmias or cardiac arrest</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac index</measure>
    <time_frame>at 6 h after ICU admission, and at the beginning of POD 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>At the beginning of POD 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak serum creatinine concentration</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of acute kidney injury</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment score</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day all-cause mortality</measure>
    <time_frame>30 days after randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Cardiac Surgical Procedures</condition>
  <condition>Heart Valve Prosthesis Implantation</condition>
  <arm_group>
    <arm_group_label>Phosphocreatine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomly assigned to the phosphocreatine arm receive:&#xD;
after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV);&#xD;
together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L);&#xD;
immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV;&#xD;
immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomly assigned to the placebo arm receive:&#xD;
after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;&#xD;
together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany);&#xD;
immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;&#xD;
immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phosphocreatine sodium tetrahydrate after anaesthesia induction</intervention_name>
    <description>after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)</description>
    <arm_group_label>Phosphocreatine</arm_group_label>
    <other_name>Neoton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% Glucose after anaesthesia induction</intervention_name>
    <description>after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Dextrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phosphocreatine sodium tetrahydrate added to cardioplegia</intervention_name>
    <description>together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)</description>
    <arm_group_label>Phosphocreatine</arm_group_label>
    <other_name>Neoton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% Glucose</intervention_name>
    <description>together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany)</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Dextrose added to cardioplegia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phosphocreatine sodium tetrahydrate after heart recovery</intervention_name>
    <description>immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV</description>
    <arm_group_label>Phosphocreatine</arm_group_label>
    <other_name>Neoton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% Glucose after heart recovery</intervention_name>
    <description>immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Dextrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phosphocreatine sodium tetrahydrate after ICU admission</intervention_name>
    <description>immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV</description>
    <arm_group_label>Phosphocreatine</arm_group_label>
    <other_name>Neoton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% Glucose after ICU admission</intervention_name>
    <description>immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Dextrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Double/triple valve lesion that required cardiac surgery with CPB&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Concomitant coronary artery bypass grafting surgery (CABG) or procedure on any part of&#xD;
             the aorta&#xD;
&#xD;
          -  Chronic kidney disease of G3-G4-G5 categories according to Kidney Disease: Improving&#xD;
             Global Outcomes (KDIGO) criteria (at least one of the following present for &gt; 3&#xD;
             months: glomerular filtration rate â‰¤ 60 ml/min/1.73 m2, history of kidney&#xD;
             transplantation) or solitary kidney (by any reason)&#xD;
&#xD;
          -  Known allergy to PCr&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Current enrollment into another RCT (in the last 30 days)&#xD;
&#xD;
          -  Previous enrollment and randomisation into the PRISE trial&#xD;
&#xD;
          -  Administration of PCr in the previous 30 day&#xD;
&#xD;
          -  Concomitant radiofrequency/cryo- ablation procedure&#xD;
&#xD;
          -  Structural abnormalities or genetic trait point to kidney disease including&#xD;
             glomerulonephritis and gout.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evgeny V. Fominskiy, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academician EN Meshalkin Novosibirsk Research Institute of Circulation Pathology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evgeny Fominskiy</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Horjus DL, Oudman I, van Montfrans GA, Brewster LM. Creatine and creatine analogues in hypertension and cardiovascular disease. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD005184. doi: 10.1002/14651858.CD005184.pub2. Review.</citation>
    <PMID>22071819</PMID>
  </reference>
  <reference>
    <citation>Strumia E, Pelliccia F, D'Ambrosio G. Creatine phosphate: pharmacological and clinical perspectives. Adv Ther. 2012 Feb;29(2):99-123. doi: 10.1007/s12325-011-0091-4. Review.</citation>
    <PMID>22297802</PMID>
  </reference>
  <reference>
    <citation>Landoni G, Zangrillo A, Lomivorotov VV, Likhvantsev V, Ma J, De Simone F, Fominskiy E. Cardiac protection with phosphocreatine: a meta-analysis. Interact Cardiovasc Thorac Surg. 2016 Oct;23(4):637-46. doi: 10.1093/icvts/ivw171. Epub 2016 Jun 17. Review.</citation>
    <PMID>27318357</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Meshalkin Research Institute of Pathology of Circulation</investigator_affiliation>
    <investigator_full_name>Vladimir Lomivorotov</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Phosphocreatine</keyword>
  <keyword>Creatine Phosphate</keyword>
  <keyword>Neoton</keyword>
  <keyword>Phosphate, Creatine</keyword>
  <keyword>Phosphorylcreatine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phosphocreatine</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

